Investigational drug · Phase 3
Gocatamig
Also called: HPN328, MK-6070, DS-3280
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Small-Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "Gocatamig"
First trial start
2020
Dec 14, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Gocatamig", any sponsor or status.
Conditions studied
As listed on its trial records.
- Small Cell Lung Cancer
- Small Cell Lung Cancer Extensive Stage
- Small-Cell Lung Cancer
- Neuroendocrine Carcinoma
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Gocatamig" as an intervention, largest first.
- A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07908537 · 564 participants (planned) · Start Dec 7, 2026 · Primary completion Dec 8, 2031
Drug: Gocatamig; Durvalumab and 1 more · For: Small Cell Lung Cancer
- A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06780137 · 327 participants (planned) · Start Feb 27, 2025 · Primary completion Feb 15, 2029
Drug: Gocatamig; Ifinatamab Deruxtecan (I-DXd) and 1 more · For: Small Cell Lung Cancer
Sites: Aurora, Colorado; Miami, Florida; Chicago, Illinois · 48 sites in all
- A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)Active, not recruiting
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT04471727 · 232 participants (planned) · Start Dec 14, 2020 · Primary completion Jan 28, 2028
Drug: Gocatamig; Atezolizumab and 1 more · For: Small-Cell Lung Cancer; Neuroendocrine Carcinoma
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 11 sites in all
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07227597 · 170 participants (planned) · Start Jan 29, 2026 · Primary completion Nov 29, 2030
Drug: Gocatamig; I-DXd and 4 more · For: Small Cell Lung Cancer Extensive Stage
Sites: Santa Rosa, California; Aurora, Colorado; Orlando, Florida · 58 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- T-cell engagers in small-cell lung cancer: current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation Workshop.
Meyer ML, Peters S, Ahn MJ, et al. · Cancer Treat Rev 2026
- The rise of bispecific antibodies for dual targeting, singular impact: technology and clinical advancements.
Pandey A, Wankhade S, Murthy A, et al. · Int Immunopharmacol 2026
- Structural and functional insights into CD3 bispecific antibodies targeting DLL3 in cancer immunotherapy.
Chen S, Zhang G, He X, et al. · Med Oncol 2026
- Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer.
Ku SY, Manzar N, Garcia MM, et al. · Mol Cancer Ther 2026
- Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer.
Ji K, Guo L, Zuo D, et al. · Front Immunol 2025
- HPN328, a Trispecific T Cell-Activating Protein Construct Targeting DLL3-Expressing Solid Tumors.
Molloy ME, Aaron WH, Barath M, et al. · Mol Cancer Ther 2024
Also in development for Small Cell Lung Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- ZG006Phase 38 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor
- ObrixtamigBI 764532Phase 36 trials
Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.